WITEK, Aleksandra, PARYS, Jakub, MIKOSIŃSKA, Agnieszka, KAŹMIERCZAK, Martyna, MOSSAKOWSKI, Maciej, KAŁUZIAK, Patrycja, JAJCZAK, Marta, LITWIN, Mateusz, JESIONEK, Stanisław and BIEŚ, RAfał. Vitiligo Review: etiopathogenesis, diagnosis and treatment. Quality in Sport. 2025;37:57367. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.37.57367
https://apcz.umk.pl/QS/article/view/57367

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 28.12.2024. Revised: 03.01.2025. Accepted: 03.01.2025 Published: 13.01.2025.

Vitiligo Review: etiopathogenesis, diagnosis and treatment

1. **Aleksandra Witek,**
Central Clinical Hospital of Medical University of Lodz, ul. Pomorska 251, 92-213 Łódź, Poland
https://orcid.org/0009-0002-1214-2199
aleksandra.witek98@gmail.com

2. **Jakub Parys**,
Central Clinical Hospital of Medical University of Lodz,
ul. Pomorska 251, 92-213 Łódź, Poland
https://orcid.org/0009-0009-1955-7865
kubap1812@gmail.com

3. **Agnieszka Mikosińska**,
Central Clinical Hospital of Medical University of Lodz, ul. Pomorska 251, 92-213 Łódź, Poland
https://orcid.org/0009-0003-0891-9089
agnieszka.mikosinska@stud.umed.lodz.pl

4. **Martyna Kaźmierczak**,
Central Clinical Hospital of Medical University of Lodz, ul. Pomorska 251, 92-213 Łódź, Poland
https://orcid.org/0009-0007-7798-0069
martyna.kazmierczak@stud.umed.lodz.pl

5. **Patrycja Kałuziak**,
Charles Jonscher Medical Center,
ul. Milionowa 14, 93-113 Łódź, Poland
https://orcid.org/0009-0008-0976-1523
patrycjakaluziak@o2.pl

6. **Marta Jajczak,**
University Clinical Hospital No.2 of Medical University of Lodz, ul. Żeromskiego 113, 90-549 Łódź, Poland
https://orcid.org/0009-0009-6000-7769
jajmarta@gmail.com

7. **Maciej Mossakowski,**
Central Clinical Hospital of Medical University of Lodz, ul. Pomorska 251, 92-213 Łódź, Poland
https://orcid.org/0009-0008-0423-2083
macmos@op.pl

8. **Mateusz Litwin**,
University Clinical Hospital No.2 of Medical University of Lodz, ul. Żeromskiego 113, 90-549 Łódź, Poland
https://orcid.org/0009-0006-5131-1 863
mateusz.litwin@stud.umed.lodz.pl

9. **Stanisław Jesionek**,
Pabianice Medical Center Sp. o.o.,
ul. Jana Pawła II 68, 95-200 Pabianice, Poland
https://orcid.org/0009-0004-6026-702X
stanislawjesionek@wp.pl

10. **Rafał Bieś**,
Medical University of Silesia, Faculty of Medical Sciences in Katowice,
ul. Medyków 18, 40-752 Katowice, Poland
https://orcid.org/0009-0005-0583-6661
rafal.bies01@gmail.com

ABSTRACT

Introduction and purpose: This review is intended for healthcare professionals, including dermatologists, primary care physicians, and researchers, who seek a comprehensive understanding of vitiligo. It is also relevant for patients and their families to better understand the condition. The review is indicated for those dealing with cases of vitiligo that are difficult to diagnose or manage, those with widespread or refractory vitiligo, and individuals interested in the latest advancements in treatment. The purpose of this review is to provide a detailed analysis of vitiligo's etiopathogenesis, the current diagnostic methods, and the most effective treatment options. By exploring the genetic, autoimmune, and environmental factors involved in vitiligo, the review aims to enhance the understanding of the disease's origin and progression. Additionally, it seeks to offer evidence-based insights into the most up-to-date diagnostic tools and therapeutic approaches, ultimately improving patient care and guiding future research directions.

State of knowledge:

Vitiligo is an autoimmune disorder characterized by the loss of melanocytes, leading to depigmented skin patches. Its exact cause remains unclear, but genetic and environmental factors, such as stress and skin trauma, are thought to contribute. Diagnosis is primarily clinical, with dermoscopy and biopsy used in uncertain cases. While treatments like topical corticosteroids, phototherapy, and JAK inhibitors are effective for some, no cure exists, and responses vary widely. Surgical options like melanocyte transplantation can help with localized cases. Ongoing research aims to better understand the disease mechanisms and improve treatment outcomes.

Methods: A comprehensive search of references related to vitiligo and other depigmentation diseases was conducted on PubMed using the following search terms: "vitiligo, phototherapy, autoimmune diseases, melanocytes, corticosteroids."

Keywords: vitiligo, phototherapy, autoimmune diseases, melanocytes, corticosteroids

I. Introduction

A. Definition of Vitiligo

Vitiligo is a long-lasting skin condition characterized by the progressive loss of pigmentation in patches of skin, resulting in stark white areas [17]. This occurs due to the destruction or dysfunction of melanocytes, the cells responsible for producing melanin, which gives skin its color. Vitiligo can affect people of all skin types and ages, and it is not contagious or life-threatening [22].

1. Types of Vitiligo [20]

- Localized Vitiligo: This type is limited to specific areas on the body. Subtypes include:
    - Focal Vitiligo: Shows a few depigmented spots in one or more areas.
    - Segmental Vitiligo: Depigmentation occurs in a localized area on one side of the body and tends to stabilize over time [5].
- Generalized Vitiligo: The most common form, it manifests as widespread patches on both sides of the body. It can progress and vary in severity [8].

- Universal Vitiligo: A rare form involving near-complete or complete depigmentation of the skin across the entire body [1].

2. Clinical Features
   - The condition typically begins with small, pale spots that gradually become more widespread. These spots have well-defined edges and can vary in size.
   - Vitiligo may also affect mucous membranes, hair (resulting in white or gray hair), and the retina [29].

3. Impact on Patients
   - Vitiligo can lead to significant psychological distress due to its visible nature, affecting self-esteem and social relationships.
   - The stigma associated with skin disorders can lead to anxiety, depression, and a desire for cosmetic treatment among affected individuals [32].

4. Pathophysiology Overview
   - The pathophysiological processes leading to vitiligo are complex and multifactorial, involving genetic predisposition, environmental factors, and autoimmune responses. This complexity underscores the importance of understanding the condition fully for effective management and treatment [3].

B. Epidemiology and demographics

Vitiligo affects approximately 0.5–1% of the global population, making it the most common depigmentation disorder. Its prevalence varies by region, with India having the highest rate, affecting around 8.8% of the population. [1] The condition typically presents early, with 70 - 80% of cases diagnosed before age 30. Vitiligo affects both men and women equally, though women may experience earlier onset, particularly during hormonal changes like pregnancy or menopause [25]. The disease is more noticeable in individuals with darker skin, as depigmented patches contrast more sharply. Vitiligo not only impacts physical appearance but also carries significant psychological challenges, leading to higher rates of anxiety, depression, and social isolation. Early diagnosis and comprehensive care, addressing both medical and emotional aspects, are crucial for improving patient outcomes [21].

II. Etiopathogenesis

The etiology of vitiligo is multifactorial, encompassing genetic, immunological, and environmental factors [2]. Genetic predisposition plays a significant role, with certain gene variations linked to an increased susceptibility to the condition. Autoimmune mechanisms are also implicated, where the immune system mistakenly attacks melanocytes, leading to depigmentation. Additionally, environmental triggers such as sunburn, stress, and chemical exposure may exacerbate or precipitate the onset of vitiligo [9]. Ongoing research continues to explore the interactions between these factors, aiming to illuminate the underlying pathways involved in the disease's progression and create targeted therapeutic approaches.

A. Genetic Factors

The genetic component of vitiligo is a significant aspect of its etiology, suggesting that a hereditary predisposition plays a crucial role in its development [8]. Studies have shown that individuals with a family history of vitiligo or other autoimmune diseases, such as thyroid disorders or type 1 diabetes, are at higher risk for developing the condition. Genome-wide association studies (GWAS) have identified several susceptibility loci associated with vitiligo, with prominent genes including those linked to immune regulation, melanocyte function, and oxidative stress. Notably, variations in genes such as the NLRP1, TYR, and HLA (human leukocyte antigen) genes have been implicated, reflecting the intricate interplay between genetic susceptibility and immune system dysregulation [4].

Moreover, epigenetic factors, which refer to changes in gene expression without altering the DNA sequence itself, may also contribute to vitiligo. These alterations can be influenced by environmental factors such as UV exposure or stress, leading to the activation or silencing of specific genes involved in pigmentation and immune response. Understanding the genetic basis of vitiligo not only aids in identifying at-risk individuals but also provides insights into potential therapeutic targets, paving the way for personalized medicine approaches in its treatment. Overall, continued research into the genetic underpinnings of vitiligo is essential for unraveling its pathogenesis and improving management strategies for affected individuals [2][13].

B. Environmental Triggers

1. Sunburn and skin trauma

Sunburn plays a notable role in the etiology of vitiligo, particularly due to its capacity to induce skin trauma and inflammation, which can activate the immune system and results in the localized destruction of melanocytes [9]. When the skin is subjected to UV radiation, it responds by releasing inflammatory mediators and cytokines, which can trigger an immune response that may target the body's own melanocytes, the cells responsible for producing skin pigment [11]. This autoimmune reaction is especially concerning in individuals with a genetic susceptibility to vitiligo.

Moreover, areas of the skin that have been sunburned may become more vulnerable to further depigmentation, as the initial damage can alter the normal healing process and disrupt the function and survival of melanocytes. The subsequent inflammation can lead to depigmented patches known as "hypopigmented macules," which may eventually expand into more significant areas of vitiligo. This phenomenon can manifest the Koebner response, where skin lesions appear in areas affected by trauma, including sunburn [3].

Preventive measures, such as rigorous sun protection and avoiding prolonged sun exposure, are key for individuals at risk of vitiligo, as minimizing skin damage can help preserve the function of melanocytes and potentially reduce the risk of new lesions forming. Understanding the relationship between sunburn and vitiligo reinforces the importance of sun safety and the need for protective strategies in susceptible populations.

2. Stress and psychological factors

Stress and psychological factors have been increasingly recognized as playing a significant role in the etiopathogenesis of vitiligo, a skin condition characterized by the progressive loss of melanocytes, leading to depigmented patches on the skin.

Several studies suggest that stress, particularly emotional and psychological stress, can trigger or exacerbate the development of vitiligo in genetically predisposed individuals. Stress-induced mechanisms, such as the activation of the hypothalamic-pituitary-adrenal (HPA) axis and the release of pro-inflammatory cytokines, may contribute to immune dysregulation, which in turn accelerates the destruction of melanocytes. Additionally, psychological factors like anxiety and depression can affect the autonomic nervous system, leading to disturbances in skin pigmentation. While stress alone is not a direct cause of vitiligo, it appears to act as an important environmental trigger or exacerbating factor, influencing both the onset and progression of the disease. This highlights the need for a holistic approach in managing vitiligo, addressing both physical and psychological aspects of the condition [32].

3. Chemical exposure

Chemical factors play a significant role in the onset and progression of vitiligo, especially in genetically predisposed individuals. Exposure to chemicals like phenolic compounds (found in hair dyes and disinfectants), aromatic hydrocarbons, and pesticides can damage melanocytes or trigger immune responses that lead to their destruction. These chemicals induce oxidative stress, disrupting the balance between free radicals and antioxidants, which damages melanocytes and accelerates the breakdown of melanin. In some cases, chemicals act as haptens, altering skin proteins and prompting autoimmune reactions that destroy melanocytes. Occupations with frequent chemical exposure, such as hairdressing, painting, and farming, increase the risk of developing vitiligo. Certain topical products, including cosmetics and sunscreens, can also trigger or worsen the condition in sensitive individuals. Understanding these environmental triggers is essential for risk reduction and developing safer practices in both occupational and consumer settings [14].

C. Autoimmune Mechanisms

The autoimmune aspect of vitiligo is a critical component of its etiopathogenesis, revealing how the body's immune system can mistakenly target and destroy its own melanocytes, the pigment-producing cells of the skin. This autoimmune response is characterized by the activation of specific immune cells, particularly CD8+ T-lymphocytes, which infiltrate the skin and recognize melanocytes as foreign entities. This aberrant immune activity leads to the destruction of melanocytes and, consequently, the loss of skin pigmentation [16].

Research has identified the presence of autoreactive T cells in the skin lesions of vitiligo patients, suggesting that these cells may play a pivotal role in the pathophysiology of the condition. Furthermore, various cytokines, such as interferon-gamma and tumor necrosis factor-alpha, are upregulated in vitiligo, promoting inflammation and further damaging melanocytes. The interplay between genetic factors and immune responses is integral to understanding why some individuals develop vitiligo while others do not, even when exposed to similar triggers [7].

In addition to T cell-mediated damage, the role of autoantibodies in vitiligo is also under investigation. Some studies have reported the presence of antibodies targeting melanin-related proteins, which could contribute to the immune system's attack on melanocytes.

This autoimmune phenomenon can often be associated with other autoimmune disorders, including autoimmune thyroid disease and systemic lupus erythematosus, indicating that typologies of autoimmunity may share common pathways or triggers that contribute to the development of vitiligo [8].

Current treatment approaches for vitiligo, such as corticosteroids, calcineurin inhibitors, and phototherapy, also take into account the autoimmune nature of the disease. By modulating the immune response, these therapies aim to reduce inflammation and promote repigmentation. Understanding the autoimmune mechanisms underlying vitiligo continues to be a focus of research, as it may lead to the identification of novel therapeutic targets and strategies that can more effectively manage this challenging condition [10].

D. Other Contributing Factors

1. Hormonal changes

Hormonal changes play a key role in the development and progression of vitiligo, particularly during periods of significant hormonal fluctuations such as puberty, pregnancy, and menopause. These changes can impact immune regulation, melanocyte function, and oxidative stress, potentially triggering or worsening vitiligo in genetically predisposed individuals. For instance, estrogen influences melanocyte survival and function, with higher levels during pregnancy or when using oral contraceptives often associated with the onset or exacerbation of vitiligo. Conversely, testosterone may affect melanocyte activity and immune response, though its role is less understood [34].

There is also a strong link between thyroid hormones and vitiligo, particularly in patients with autoimmune thyroid diseases like Hashimoto's thyroiditis or Graves' disease, which can worsen autoimmune attacks on melanocytes. Hormonal fluctuations can also increase oxidative stress, a key factor in melanocyte destruction, by disrupting the balance between free radicals and antioxidants, leading to cellular damage [8].

Understanding the relationship between hormones and vitiligo is crucial for developing more personalized treatments, as targeting hormonal imbalances or modifying hormonal pathways may improve treatment outcomes. Future research will likely uncover new therapeutic targets, offering more effective and individualized approaches to managing vitiligo.

2. Viral infections

Viral infections have been suggested as potential environmental triggers for vitiligo, particularly in genetically predisposed individuals, and may play a significant role in both the onset and exacerbation of the disease. Several studies have linked viral infections such as human herpes simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and even cytomegalovirus (CMV) with the development of vitiligo. These infections can lead to an inflammatory response that disrupts immune homeostasis, triggering autoimmune mechanisms that specifically target melanocytes, the pigment-producing cells of the skin.

The underlying pathophysiology could involve a process known as molecular mimicry, where the immune system, after recognizing viral antigens, mistakenly begins to attack melanocytes due to structural similarities between the viral proteins and melanocyte components. This autoimmune response may result in the gradual loss of melanocytes in affected areas of the skin, leading to the characteristic white patches of vitiligo.

In addition to immune system dysregulation, viral infections can induce oxidative stress in the body, which may further damage melanocytes. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them with antioxidants, leading to cellular damage. In melanocytes, this stress can trigger cellular apoptosis (programmed cell death) or make the cells more vulnerable to immune attack. Furthermore, certain viral infections, such as herpes simplex or varicella-zoster, are known to cause skin lesions that may precede or coincide with vitiligo in some cases, suggesting that these viral infections could directly affect the skin's pigmentation.

Interestingly, the role of viral infections in vitiligo seems to be most relevant during periods of viral flare-ups, when the body’s immune system is under significant strain. It is thought that these infections may "unmask" underlying genetic susceptibilities, accelerating the development of vitiligo or exacerbating existing symptoms. Some studies have also indicated that the timing of a viral infection may be important, with infections during childhood or adolescence potentially having a greater impact on the risk of developing vitiligo compared to infections later in life.

While viral infections alone are unlikely to be the sole cause of vitiligo, they appear to act as significant environmental triggers, especially in individuals with a family history of autoimmune conditions or those with specific genetic variants that predispose them to immune dysfunction. Understanding the relationship between viral infections and vitiligo is important for developing preventive strategies and treatment approaches, particularly in individuals who are more susceptible to autoimmune diseases. Furthermore, addressing viral infections and their complications, through antiviral treatments or vaccination where appropriate, could potentially reduce the risk of vitiligo or prevent its progression in at-risk populations [33].

III. Diagnosis

A. Clinical Assessment

The clinical assessment of vitiligo involves a thorough evaluation of the patient's skin, medical history, and symptom progression. It begins with a visual inspection to identify the characteristic depigmented patches, which are typically well-defined and appear on sun-exposed areas like the face, hands, and feet. The distribution of lesions is often bilateral, though localized forms can occur. Lesions may start as small spots and gradually expand, with well-defined borders distinguishing vitiligo from other conditions [29].

The Koebner phenomenon, where new lesions appear at sites of skin trauma, is a key feature of vitiligo. The location of lesions, such as in areas of friction or near mucosal surfaces, is important for diagnosis. Tools like the VASI and VSS scoring systems help assess the extent and severity of the disease [30].

A detailed medical history is crucial, as vitiligo is often associated with autoimmune conditions like thyroid disorders or diabetes. The clinician also considers any triggers, such as stress or injury, and asks about family history, since vitiligo can be hereditary [18].

Evaluation of skin type helps understand the cosmetic impact, as depigmentation is more noticeable in lighter skin. Finally, a psychological assessment is essential, as vitiligo can significantly affect self-esteem and quality of life. This comprehensive evaluation aids in differentiating vitiligo from other conditions and informs treatment strategies.

B. Differential Diagnosis

The differential diagnosis of vitiligo is crucial, as several skin conditions can present with similar depigmented patches. Key conditions to differentiate from vitiligo include:

- Pityriasis alba: Often seen in children, with light, scaly patches that are less sharply defined and tan with sun exposure. It responds to emollients or mild corticosteroids, unlike vitiligo.
- Tinea versicolor: A fungal infection with hypo- or hyperpigmented patches, usually with a fine scale that is scraped off, and it responds to antifungal treatments.
- Leprosy: Causes hypopigmented patches with sensory loss, thickened skin, and neuropathy, which is not seen in vitiligo. Diagnosis is confirmed by skin tests.
- Post-inflammatory hypopigmentation: Occurs after skin trauma or inflammation and is localized. Unlike vitiligo, it typically regains pigmentation as healing progresses.
- Albinism: A genetic condition causing generalized skin and hair depigmentation from birth, unlike vitiligo, which develops over time in specific areas.
- Contact dermatitis: Skin lightening following chemical or allergen exposure, often with redness and itching during the inflammatory phase, unlike vitiligo's absence of inflammation.
- Other conditions, such as seborrheic dermatitis, psoriasis, eczema, sarcoidosis, and lupus, can also mimic vitiligo but usually present with distinct features like erythema, scaling, or systemic symptoms.

A thorough clinical evaluation, including patient history, physical examination, and diagnostic tests (e.g., Wood's lamp, skin biopsy, and blood tests), is essential for accurate diagnosis and treatment [27].

C. Diagnostic Tools

The diagnosis of vitiligo is primarily clinical, based on its characteristic depigmented patches, but various diagnostic tools can confirm the diagnosis and assess the extent of the condition.

- Wood's Lamp: A UV light that helps highlight depigmented areas, making early vitiligo lesions more visible. It distinguishes vitiligo from conditions like tinea versicolor by the fluorescence pattern [6].
- Skin Biopsy: Used when the diagnosis is unclear, it reveals the absence of melanocytes and can show immune-mediated changes, confirming vitiligo and excluding conditions like leprosy [6].
- Blood Tests: These help identify associated autoimmune diseases like thyroid disorders, type 1 diabetes, or Addison's disease, common in vitiligo patients. Tests include thyroid function, ANA, CBC, and glucose levels [6].
- Immunohistochemistry: Used in ambiguous cases, this method confirms the absence of melanocytes and assesses immune cell activity in affected areas [6].
- Autofluorescence Spectroscopy: A non-invasive technique that measures melanin levels, useful for monitoring depigmentation and treatment response [6].
- Genetic Testing: May be used in cases with a strong family history or early onset to identify genetic risk factors for vitiligo [6].

- Dermoscopy: Assesses the edges of depigmented patches to help differentiate vitiligo from other skin conditions like melanomaC][19].
- Psychological Evaluation: Since vitiligo can impact self-esteem and mental health, psychological assessments help address emotional and social effects [6][32].

These diagnostic tools, combined with clinical evaluation, ensure accurate diagnosis and guide treatment decisions for vitiligo [6].

IV. Treatment Options

A. Topical Treatments

Topical treatments for vitiligo are often the first-line therapy for localized or mild cases. These aim to restore pigmentation, reduce inflammation, and modulate the immune response. The effectiveness of these treatments varies depending on the extent of the condition, the patient's age, and the areas affected. Key topical options include:

1. Topical Corticosteroids: These reduce inflammation and immune response, potentially promoting repigmentation. They are most effective for localized vitiligo but can cause side effects like skin thinning with long-term use [27].
2. Topical Calcineurin Inhibitors (TCIs): Drugs like tacrolimus and pimecrolimus modulate the immune system and are particularly useful in sensitive areas (e.g., face). They are steroid-free but can increase the risk of skin infections with long-term use [27][28].
3. Topical Psoralen + UVA (PUVA): Psoralen makes the skin more sensitive to UVA light, promoting repigmentation. It is effective for small, stable lesions but requires repeated treatments and carries risks of skin irritation and long-term damage [31].
4. Topical Vitamin D Analogs: Used off-label for vitiligo, these drugs like calcipotriene promote melanocyte function and may help repigmentation, though their effectiveness is still being studied [28][23] .
5. Topical JAK Inhibitors: Ruxolitinib, a newly FDA-approved drug, blocks inflammatory pathways to promote repigmentation. It has shown good results within 2-3 months and offers a more targeted approach with fewer side effects [23][26].
6. Topical Retinoids: Tretinoin can stimulate melanocyte activity and enhance the effects of other treatments, though it may cause skin irritation [20] [28].

B. Phototherapy

Phototherapy is a key treatment for vitiligo, especially for moderate to widespread cases. It uses specific light wavelengths to stimulate melanocyte function, promote repigmentation, and modulate the immune response. The main types of phototherapy for vitiligo include narrowband UVB (NB-UVB), psoralen + UVA (PUVA), and excimer laser therapy.

1. Narrowband UVB (NB-UVB): This is the most common and well-studied option. NB-UVB light stimulates melanocytes and reduces the immune response. Treatment typically involves 2-3 sessions per week, with noticeable results in 3-6 months. Side effects include skin irritation and a slightly increased risk of skin cancer [24].
2. Psoralen + UVA (PUVA): PUVA combines psoralen, which makes skin sensitive to UVA light, with UVA exposure. It’s effective for more extensive or stable vitiligo but carries higher risks, including skin aging, skin cancer, and cataracts. Patients are closely monitored, and protective measures are recommended [20].

3. Excimer Laser Therapy: This delivers targeted UVB light to specific areas, making it ideal for localized vitiligo. It's effective for small, stable lesions, with repigmentation often visible after 12-24 sessions. Side effects include skin irritation or the risk of hyperpigmentation [28][26].
4. Home-Based Phototherapy: For patients needing frequent treatments, home-based NB-UVB units are available. They offer convenience but require careful monitoring to avoid overexposure and skin damage[28].

C. Systemic Treatments

Systemic treatments for vitiligo are used when topical therapies and phototherapy are insufficient, particularly in severe or rapidly progressing cases. These treatments target the immune response, promote melanocyte regeneration, and manage systemic inflammation. They are mainly for generalized, segmental, or extensive vitiligo, including vitiligo universalis. Key systemic treatments include oral corticosteroids, immunosuppressive agents, JAK inhibitors, systemic PUVA, vitamin D analogs, and monoclonal antibodies.

1. Oral Corticosteroids: Used for severe, rapidly progressing vitiligo, they reduce inflammation and immune activity. They can promote repigmentation in active lesions but are limited for stable areas due to significant side effects (e.g., weight gain, hypertension). Short-term use is preferred [15].
2. Immunosuppressive Agents: Drugs like methotrexate and azathioprine help reduce T-cell activity that damages melanocytes. These are used for extensive or refractory vitiligo. They can promote repigmentation but require careful monitoring for side effects, such as liver toxicity and increased infection risk [6][26].
3. JAK Inhibitors: Drugs like ruxolitinib target immune pathways to reduce melanocyte destruction and restore function. They have shown promise in repigmenting generalized or progressive vitiligo within 3-6 months but carry risks like immunosuppression and infection [10][15].
4. Systemic PUVA: This involves taking oral psoralen followed by UVA light exposure. It is effective for widespread vitiligo, especially when other treatments fail. However, it carries risks of skin aging, skin cancer, and eye damage, requiring strict monitoring [10].
5. Vitamin D Analogues: These include drugs like calcipotriene, which may promote melanocyte function and modulate the immune system. Their use is less established, but they may benefit some patients when combined with other therapies. Side effects like hypercalcemia are possible [20].
6. Monoclonal Antibodies (e.g., Dupilumab): Dupilumab, which targets immune cytokines (IL-4, IL-13), is showing promise in reducing inflammation and improving pigmentation. It's generally used for severe cases when other treatments fail, but more research is needed [20][12].

D. Surgical Interventions

Surgical interventions for vitiligo are considered for patients with localized, stable, or unresponsive vitiligo, particularly when other treatments fail or when cosmetic improvement is a priority.

These methods are effective for small, stable lesions, and include skin grafting, melanocyte transplantation, autologous epidermal cell suspension, and less commonly, blister grafting and tattooing.

1. Skin Grafting: Involves transplanting healthy pigmented skin to depigmented areas. Types include thin split-thickness grafting for larger areas and punch grafting for small lesions. Indications: Best for stable, localized vitiligo, especially in hard-to-treat areas like the face and hands. Efficacy: Can offer good cosmetic results, but repigmentation may vary. Complications: Risks include infection, graft rejection, and color mismatch.
2. Melanocyte Transplantation: Melanocytes from pigmented skin are cultured and transplanted to depigmented areas. Indications: Ideal for stable, small-to-medium patches unresponsive to other treatments. Efficacy: Often results in good repigmentation and cosmetic improvement. Complications: Potential risks include infection, scarring, and color mismatch.
3. Autologous Epidermal Cell Suspension: A less invasive option, this involves culturing epidermal cells from the patient's own skin and applying them to depigmented areas. Indications: Suitable for stable, widespread vitiligo. Efficacy: Shows promising results with gradual repigmentation. Complications: Risks include infection and poor graft survival, though it's less invasive than skin grafting.
4. Blister Grafting: Involves transferring the blister roof from pigmented skin to depigmented areas. Indications: Used for small, localized lesions. Efficacy: Slower results compared to other methods but can lead to localized repigmentation.
5. Tattooing: Used for small, localized areas to camouflage depigmented patches. Indications: Ideal for facial vitiligo or small patches. Efficacy: Provides cosmetic camouflage but doesn't restore true pigmentation. Complications: Risks include infection and color mismatch, and the pigment may fade over time.

Surgical interventions are effective for stable, localized vitiligo when other treatments fail. Skin grafting, melanocyte transplantation, and epidermal cell suspension offer long-term cosmetic improvements, though they carry risks like infection and scarring. Patients should be carefully assessed for suitability based on lesion type, stability, and treatment goals [35] .

E. Cosmetic Approaches

Cosmetic approaches to managing vitiligo focus on improving appearance and enhancing quality of life, particularly when medical treatments are ineffective or the disease is stable. These methods help camouflage depigmented patches, boosting confidence. Common cosmetic treatments include makeup, self-tanning, tattooing, and laser therapy.

1. Makeup and Camouflage Products: Specialized makeup covers vitiligo patches. Indications: Effective for small, localized areas, like the face or hands. Efficacy: Provides good coverage but requires reapplication and doesn't address the underlying cause.
2. Self-Tanning Products: Self-tanners darken skin to blend depigmented areas with surrounding skin. Indications: Suitable for localized vitiligo. Efficacy: Offers temporary cosmetic improvement, but needs frequent reapplication and fades over time.

3. Tattooing (Micropigmentation): Permanent pigments are implanted into depigmented skin. Indications: Ideal for stable, localized lesions, particularly on the face or hands. Efficacy: Long-lasting results, though color mismatch and fading can occur. Not suitable for active vitiligo.
4. Depigmentation Therapy: Involves lightening the remaining pigmented skin to achieve a uniform tone. Indications: Used for widespread vitiligo (vitiligo universalis). Efficacy: Provides an even skin tone, but is irreversible and may cause skin irritation.
5. Laser Therapy: Fractional lasers stimulate melanin production in affected areas. Indications: Best for small, stable patches. Efficacy: Can improve pigmentation but may require multiple sessions and may not work for larger areas[12].

Cosmetic treatments like makeup, self-tanning, tattooing, and laser therapy offer temporary solutions for improving the appearance of vitiligo. While they don't address the underlying cause, these options can help patients regain confidence and manage the cosmetic effects of the condition. Combining them with medical therapies can provide more effective long-term management [10][32].

V. Conclusion

Vitiligo is a complex, multifactorial disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes. Its pathogenesis involves a combination of genetic, autoimmune, oxidative stress, neurohumoral, and environmental factors, which interact in diverse ways to trigger or exacerbate the condition. Research has demonstrated the role of both immune-mediated mechanisms and intrinsic melanocyte dysfunction in vitiligo, with recent advances in understanding the molecular and genetic underpinnings offering promising avenues for future therapies.

The diagnosis of vitiligo remains primarily clinical, based on patient history and physical examination, with various diagnostic tools such as the Wood's lamp, dermatoscopy, and biopsy providing supplementary information. Given the heterogeneous nature of vitiligo, distinguishing it from other hypopigmentary skin disorders is crucial for accurate diagnosis and appropriate management. Early diagnosis can help initiate timely treatments, which can potentially limit the progression of the disease and improve long-term outcomes.

Treatment options for vitiligo are varied and tailored to the extent and severity of the disease, as well as the patient's preferences.

Topical therapies, such as corticosteroids and calcineurin inhibitors, remain the mainstay of treatment, while phototherapy offers a promising option for widespread vitiligo. For cases that are resistant to medical treatments, systemic therapies and surgical interventions like skin grafting or melanocyte transplantation provide additional avenues for repigmentation. Additionally, cosmetic approaches, including the use of makeup, self-tanning products, and tattooing, play an essential role in managing the psychosocial impact of vitiligo and improving quality of life. Despite the availability of various therapeutic options, challenges remain in providing personalized care for vitiligo patients, as treatments may vary in efficacy based on disease type, patient factors, and the location of lesions. As our understanding of the etiopathogenesis of vitiligo continues to evolve, future research focused on targeted therapies - including gene editing and immunomodulatory approaches - holds great promise in improving the outcomes for individuals living with this complex and often disfiguring condition.

In conclusion, while vitiligo remains a challenging condition with a multifactorial etiology and varied clinical course, advancements in our understanding of its underlying mechanisms, coupled with a growing arsenal of therapeutic options, offer hope for more effective and individualized treatment strategies. Comprehensive care that addresses both the biological and psychosocial aspects of vitiligo will be key to improving patient outcomes and quality of life.

Disclosure: Authors do not report any disclosures.
Authors' contribution:
Conceptualization: Aleksandra Witek
Methodology: Martyna Kaźmierczak, Stanisław Jesionek
Formal Analysis: Aleksandra Witek, Agnieszka Mikosińska
Sources: Marta Jajczak, Mateusz Litwin
Visualization: Mateusz Litwin, Maciej Mossakowski
Investigation: Jakub Parys, Patrycja Kałuziak
Supervision: Marta Jajczak, Martyna Kaźmierczak
Validation: Agnieszka Mikosińska, Stanisław Jesionek
Writing – Original Draft: Aleksandra Witek
Writing – Review & Editing: Agnieszka Mikosińska, Stanisław Jesionek
Project administration: Patrycja Kałuziak, Jakub Parys

All authors have read and agreed with the published version of the manuscript.

Funding statement:
No funding was received.

Institutional Review Board Statement:
Not applicable.

Informed Consent Statement:
Not applicable.

Data availability statement:
Not applicable.

Acknowledgments:
Not applicable.

Conflict of interest:
The authors declare no conflict of interest.

VI. References

1. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. doi: 10.1159/000506103. Epub 2020 Mar 10. PMID: 32155629.
2. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-648. doi: 10.1146/annurev-immunol-100919-023531. Epub 2020 Feb 4. PMID: 32017656.
3. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021 Mar;48(3):252-270. doi: 10.1111/1346-8138.15743. Epub 2021 Jan 6. PMID: 33404102.
4. Spritz RA, Santorico SA. The Genetic Basis of Vitiligo. J Invest Dermatol. 2021 Feb;141(2):265-273. doi: 10.1016/j.jid.2020.06.004. Epub 2020 Aug 8. PMID: 32778407.
5. van Geel N, Speeckaert R. Segmental Vitiligo. Dermatol Clin. 2017 Apr;35(2):145-150. doi: 10.1016/j.det.2016.11.005. PMID: 28317524.
6. van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, Böhm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2173-2184. doi: 10.1111/jdv.19451. Epub 2023 Sep 25. PMID: 37746876.
7. Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K. Editorial: Immunology of Vitiligo. Front Immunol. 2021 Jun 24;12:711080. doi: 10.3389/fimmu.2021.711080. PMID: 34249018; PMCID: PMC8264751.
8. van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014 Jun;28(6):741-6. doi: 10.1111/jdv.12169. Epub 2013 Apr 17. PMID: 23590677.
9. Gatti RA. Aetiology of vitiligo. Lancet. 1972 Jan 8;1(7741):91. doi: 10.1016/s0140-6736(72)90083-9. PMID: 4108962.
10. Grimes PE. Vitiligo. An overview of therapeutic approaches. Dermatol Clin. 1993 Apr;11(2):325-38. PMID: 8477546.
11. Shin JU, Roh MR, Lee JH. Vitiligo following intense pulsed light treatment. J Dermatol. 2010 Jul;37(7):674-6. doi: 10.1111/j.1346-8138.2010.00834.x. PMID: 20629836.
12. Plott RT, Wagner RF. Modern treatment approaches to vitiligo. Cutis. 1990 May;45(5):311-6. PMID: 2192829.
13. Korsunskaya IM, Suvorova KN, Dvoryankova EV. Modern aspects of vitiligo pathogenesis. Dokl Biol Sci. 2003 Jan-Feb;388:38-40. doi: 10.1023/a:1022443809606. PMID: 12705126.
14. Rmadi N, Kotti N, Bahloul E, Dhouib F, Sellami I, Sellami K, Jmal Hammami K, Masmoudi ML, Turki H, Hajjaji M. Role of chemical exposure in the incidence of

vitiligo: a case-control study in Tunisia. Libyan J Med. 2023 Dec;18(1):2132628. doi: 10.1080/19932820.2022.2132628. PMID: 36433836; PMCID: PMC9707374.
15. Mandel AS, Haberman HF, Pawlowski D, Goldstein E. Non PUVA nonsurgical therapies for vitiligo. Clin Dermatol. 1997 Nov-Dec;15(6):907-19. doi: 10.1016/s0738-081x(97)00132-6. PMID: 9404694.
16. Sehgal VN, Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol. 2006 May;45(5):583-90. doi: 10.1111/j.1365-4632.2005.02651.x. PMID: 16700798.
17. Cormane RH, Westerhof W, Siddiqui AH. Vitiligo [Vitiligo]. Ned Tijdschr Geneeskd. 1984 Sep 29;128(39):1855-9. Dutch. PMID: 6493378.
18. What you need to know about .... vitiligo. Nurs Times. 2003 Dec 9-15;99(49):27. PMID: 14705342.
19. Kumar Jha A, Sonthalia S, Lallas A, Chaudhary RKP. Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol. 2018 Jan;57(1):50-54. doi: 10.1111/ijd.13795. Epub 2017 Oct 26. PMID: 29076154.
20. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977 Sep;97(3):255-61. doi: 10.1111/j.1365-2133.1977.tb15180.x. PMID: 921895.
21. Mason SH, Cohen PR. Vitiligo. J Gt Houst Dent Soc. 1998 Feb;69(7):12-3. PMID: 9571875.
22. Kenney JA Jr. Vitiligo. Dermatol Clin. 1988 Jul;6(3):425-34. PMID: 3168334.
23. Menke HE, van Everdingen JJ. Richtlijn 'vitiligo' [The practice guideline 'vitiligo']. Ned Tijdschr Geneeskd. 2006 Sep 9;150(36):1976-81. Dutch. PMID: 17002186.
24. Wang X, McCoy J, Lotti T, Goren A. Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo. Expert Opin Pharmacother. 2014 Dec;15(18):2623-7. doi: 10.1517/14656566.2014.978287. Epub 2014 Nov 3. PMID: 25363734.
25. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol. 1997 Nov-Dec;15(6):875-8. doi: 10.1016/s0738-081x(97)00128-4. PMID: 9404690.
26. Chan MF, Chua TL. The effectiveness of therapeutic interventions on quality of life for vitiligo patients: a systematic review. Int J Nurs Pract. 2012 Aug;18(4):396-405. doi: 10.1111/j.1440-172X.2012.02047.x. PMID: 22845640.
27. Hartmann A. Vitiligo. Diagnose, Differenzialdiagnose und aktuelle Therapieempfehlungen [Vitiligo. Diagnosis, differential diagnosis, and current patient management]. Hautarzt. 2009 Jun;60(6):505-14; quiz 515. German. doi: 10.1007/s00105-009-1770-9. PMID: 19444398.
28. Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012 Aug 1;13(4):217-37. doi: 10.2165/11630540-000000000-00000. PMID: 22423621.
29. Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exp Dermatol. 2005 Jul;30(4):344-5. doi: 10.1111/j.1365-2230.2005.01779.x. PMID: 15953063.
30. Schild M, Meurer M. Vitiligo : Klinik und Pathogenese [Vitiligo: Clinical presentation and pathogenesis]. Hautarzt. 2016 Feb;67(2):173-86; quiz 187-9. German. doi: 10.1007/s00105-015-3751-5. PMID: 26781864.
31. Roohaninasab M, Mansouri P, Seirafianpour F, Naeini AJ, Goodarzi A. Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: A comprehensive

review study. Dermatol Ther. 2021 Jan;34(1):e14550. doi: 10.1111/dth.14550. Epub 2020 Dec 7. PMID: 33200859.
32. Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: Psychological impact and consequences. Dermatol Ther. 2020 May;33(3):e13418. doi: 10.1111/dth.13418. Epub 2020 May 4. PMID: 32297399.
33. Ribeiro RPS, Lacerda KAP, Guillo LA. Analysis of Serum Immunoglobulin G (IgG) Levels against Toxoplasma Gondii, Herpes Simplex Virus Types 1 and 2, Cytomegalovirus and Hepatitis C Virus in Vitiligo. Indian J Dermatol. 2023 Sep-Oct;68(5):588. doi: 10.4103/ijd.ijd_950_22. PMID: 38099098; PMCID: PMC10718258.
34. Yamamoto A, Yang L, Kuroda Y, Guo J, Teng L, Tsuruta D, Katayama I. Local Epidermal Endocrine Estrogen Protects Human Melanocytes against Oxidative Stress, a Novel Insight into Vitiligo Pathology. Int J Mol Sci. 2020 Dec 29;22(1):269. doi: 10.3390/ijms22010269. PMID: 33383933; PMCID: PMC7794688.
35. Savant SS. Surgical therapy of vitiligo: current status. Indian J Dermatol Venereol Leprol. 2005 Sep-Oct;71(5):307-10. doi: 10.4103/0378-6323.16778. PMID: 16394452.